Abstract: Provided is a fat or oil composition, comprising the following components (A) and (B): (A) 0.4 to 6 mass % of a free type triterpene alcohol; and (B) 0.2 to 3 mass of a free type phytosterol containing 20 mass % or more of ?-sitosterol, in which a content mass ratio of the free type triterpene alcohol (A) to the free type phytosterol (B), [(A)/(B)], is 0.9 or more.

Abstract: A number of variations may include a product including a fluid additive including at least one asphaltene dispersant/inhibitor including a branched dendritic core and at least one carboxylic acid moiety.

Abstract: The present invention is drawn to a process for improving the efficiency of sunscreens using a series of polyesters based upon sorbeth ethoxylates esterified with fatty acids, then crosslinked with dimer acid. These polyesters exhibit a synergistic interaction with sunscreen actives improving the efficiency providing a “shield” for the body from the harmful effects of the sun. These sorbitol alkoxylates are then reacted with dimer acid, resulting in a series of novel polyesters. The linking of the two spider esters together with dimer provide an amphilic macromolecule possessing both hydrophilic and hydrophobic portions covalently bonded to the same molecule, this provides both a boost in sun protection factor (SPF) and the ability for the sunscreen actives to be applied to wet skin.

Abstract: The invention provides compositions and methods for treating or preventing cancer with an inventive composition. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.

Abstract: Chemical compositions, lubricant compositions, and methods of using the same are provided. The lubricant composition may comprise at least on carrier. In certain methods, the lubricant composition may be provided to at least one surface, wherein the lubricant composition reduces a coefficient of friction of the at least one surface. In certain methods, the lubricant composition may be provided to at least one surface, wherein the lubricant composition reduces wear of the at least one surface.

Abstract: This invention provides a compositions for transport of a therapeutic agent. The compositions contain a therapeutic agent and a monoterpene or an analog thereof. In one aspect, the monoterpene is perillyl alcohol (POH) or an analog thereof. In one aspect, the therapeutic agent is provided in an amount effective to treat the disease or subject of choice.

Abstract: The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye tissue and/or causing yellowing of eye tissue, especially carotenoids, such as lutein and zeaxanthin.

Abstract: This invention relates to a biologically active formulation containing a conjugate of a fatty acid and a complex phenol. The fatty acid can be selected from a variety of fatty acids including acids have between 12 and 24 carbon atoms. The phenol can be a polynuclear phenol, a polyphenol or a polyfunctional phenol having a variety of substituents. The formulation can include pharmaceutically acceptable carrier, including diluent. The formulation can be provided in an active dosage form suitable to inhibit mammalian cell growth and/or metastasis of malignant cells. The formulation can be used to induce cytotoxicity in mammalian cells particularly tumor cells or to treat and prevent cellular injury or dysfunction.

Abstract: The invention provides a long acting curcumin derivative, preparation method and pharmaceutical use thereof, wherein said long acting curcumin derivative having the general structural formula disclosed herein, wherein R1 and R2 are hydrogen or methoxyl; R3 and R4 are each independently selected from C1-C50 alkyl. Compared with cuminoids, the inventive long acting curcumin derivative has a better release effect, a higher bioavailability and pharmaceutical activity, and thus can be useful for the treatment of diseases such as depression and cancer.

Abstract: An antiviral preparation comprising as an active ingredient, a phorbol derivative of formula 1: wherein is R1 is —(CH2)aX(CH2)bCH3, —(CH2)cX(CH2)dYCH3, —CO(CH2)eCH3 or —(CH2)fCH3 R2 is —CO(CH2)nCH3, R3, R4 and R5 are hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, X and Y are O or S, and each of a-f and n is a number, and having a specific safety index S.I.=CC50/EC50 of 10 or more wherein EC50 means a concentration at which HIV-1 induced cytopathogenic effect (CPE) in MT-4 cell is inhibited by 50%, and CC50 means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%. These preparations are particularly effective for human immuno-deficiency virus (HIV).

Abstract: The present invention relates to a pharmaceutical composition, a food composition or a cosmetic composition, containing one or more kinds of a compound represented by the following formula (I?) wherein R1 is a hydrogen atom, a hydroxyl group, a methoxy group or an ethoxy group, R2 is a hydroxyl group, a methoxy group or an acetoxy group, or R1 and R2 in combination optionally form a methylenedioxy group, R is represented by the following formula wherein Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=2 to 8, and R3 and R4 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that, (1) when R1 is a methoxy group, then R2 is not a hydroxyl group; and (2) when R1 is a hydroxyl group, then R2 is not a hydroxyl group and an acetoxy group.

Abstract: Disclosed are compounds comprising a benzenediol derivative bound to one or more fatty acids. Also disclosed are nutritional supplements, pharmaceutical formulations, delivery devices, and foodstuffs comprising the disclosed compounds. Methods of using the disclosed compounds and compositions to improve health are also disclosed.

Abstract: Lutein and zeaxanthin, the main carotenoids in marigold flowers, and capsanthin and capsorubin, the main carotenoids in red peppers are esterified mainly with C-18 fatty acids. The pigments were re-esterified without isolating them from the natural saponified extract using carboxylic acids in the range of C-1 to C-12 and their corresponding metallic salts in the presence of a catalyzing agent. Both the diester and monoester forms were obtained. It is expected that the pigment esters with a fatty acid of 12 or less carbons will have a better digestibility than the esters of xanthophylls in their natural state and better stability than the hydrolyzed xanthophylls. This will result in a better pigmentation capacity of the carotenoids for poultry or aquaculture.

Abstract: A personal care or cosmetic product composition that includes from about 0.1% to about 99% of at least one ester of alkoxylated aromatic alcohol and fatty carboxylic acid, and from about 0.1% to 60% of at least one functional ingredient is provided. The functional ingredients in the composition may include active ingredients and additional ingredients. Especially suitable active ingredients are sunscreen active ingredients and antiperspirant active ingredients. Preferred compositions are sunscreen product formulations and antiperspirant products. In one preferred embodiment, the composition further includes at least one cyclomethicone compound present in the amount of from about 1% to 99% by weight of the composition. A method of improving the protection of human or animal skin or hair from radiation and a method of improving the protection of human or animal skin or hair from perspiration are also provided.

Abstract: The present invention relates to a novel class of polymeric compounds having specific quaternized amine based upon a dimer acid reacted with an alkanolamine to make an ester quaternary compound. Dimer acid is a C-36 diacid having a cyclic structure and two amine groups that allow for the synthesis of a high molecular weight cationic compound which is extremely substantitive to human skin and are well tolerated by human tissue making them suitable for use preparation of barrier products for personal care applications. These materials are dimethylaminopropyl amine free, which is highly desirable in personal care applications.

Abstract: Described is a genus of E2,E4,Z8-undecatrienoic acid derivatives defined according to the structure: wherein Z represents —OR? or —NRR? with the provisos that when Z is —OR?, R? is hydrogen, C1–C6 straight chain or branched-chain alkyl or C3–C6 straight chain or branched-chain alkenyl; and when Z is —NRR?, R represents, in the alternative, hydrogen, methyl or ethyl and R? represents methyl, ethyl, n-propyl, cyclopropyl, isopropyl, n-butyl, sec-butyl, isobutyl, 2-methylbutyl, cyclobutyl, cyclopentyl or allyl. The E2,E4,Z8-undecatrienoic acid derivatives are useful in imparting, augmenting and/or enhancing flavors, aromas and somatosensory effects in or to consumable materials such as foods, beverages, skin care products, oral care products, medicinal products and the like. Also described is a synthesis process for producing such derivatives.

Abstract: The present invention refers to the use of phenolic compounds and their derivatives represented by formula I wherein R1 and R2 are selected from among: OH, OCOalkyl, or OCOalkenyl, and R3 is either H, OH, OCOalkyl or OCOalkenyl, wherein the alkyl or alkenyl chains present from 2 to 22 carbon atoms and wherein at least one OCOalkyl or OCOalkenyl group is present in the structure, for the prevention and treatment of cardiovascular, hepatic or renal diseases, as well as to their cosmetic applications, to compositions that include these compounds and to some novel phenolic compounds and derivatives.

Abstract: The invention relates to a substance which lowers LDL cholesterol levels in serum and which is fat soluble ?-sitostanol fatty acid ester, and to a method for preparing and using the same. The substance can be taken orally as a food additive, food substitute or supplement. A daily consumption of the ?-sitostanol ester in an amount between about 0.2 and about 20 g/day has been shown to reduce the absorption of biliary and endogenic cholesterol.

Abstract: Esters of alkoxylated aromatic alcohol and fatty carboxylic acid are provided. The esters are especially suitable as additives for personal care and cosmetic products. The preferred esters having an aromatic nucleus, an alkoxy spacer, an ester carboxylic group, and a fatty alkyl group, in which the aromatic nucleus and the oxygen atom of the ester carboxylic group are connected to the alkoxy spacer, and the fatty alkyl group is attached to the carbon atom of the ester carboxylic group, are also provided. Certain of the esters of alkoxylated aromatic alcohol and fatty carboxylic acid having certain skin spread factor or viscosity are also provided.

Abstract: This invention relates to a biologically active formulation containing a conjugate of a fatty acid and a complex phenol. The fatty acid can be selected from a variety of fatty acids including acids have between 12 and 24 carbon atoms. The phenol can be a polynuclear phenol, a polyphenol or a polyfunctional phenol having a variety of substituents. The formulation can include pharmaceutically acceptable carrier, including diluent. The formulation can be provided in an active dosage form suitable to inhibit mammalian cell growth and/or metastasis of malignant cells. The formulation can be used to induce cytotoxicity in mammalian cells particularly tumor cells or to treat and prevent cellular injury or dysfunction.

Abstract: Novel and nonobvious compounds that function, alone or in combination, as nuclear hormone receptors for the stimulation and/or improvement of murine, mammalian skin. Specifically, beta-ionol analog and fatty acid analog compounds that are believed to function as RXR, RAR and/or PPAR receptor ligands to encourage skin differentiation and discourage excess skin proliferation. The present invention further relates to one or more products, consumer and otherwise, comprising the novel, nuclear hormone receptor ligands disclosed herein.

Abstract: Esters derived from fatty acids and juvenoid alcohols of the general formula (I), in which X means the oxygen atom or the NH group, Y means the NH group or the oxygen atom, R means methyl, ethyl, 1-propyl, 2-methylethyl or propargyl and R′ means saturated or unsaturated alkyl with 4 to 22 carbon atoms. Esters derived from fatty acids and juvenoid alcohols are produced by a reaction of a juvenoid alcohol of the general formula (II), in which X means the oxygen atom or the NH group, Y means the NH group or the oxygen atom and R means methyl, ethyl, 1-propyl, 2-methylethyl or propargy] with a fatty acid chloride of the general formula (III): R′COC1 in which R′ means saturated or unsaturated alkyl with 4 to 22 carbon atoms, under the continuous stirring, at 0 to 70° C., using a convenient solvent, as toluene, xylene or benzene and under the presence of a base catalyst, as triethylamine, pyridine or quinoline.

Abstract: The invention relates to a novel acylate which is the reaction product of (a) a substance which is selected from the group consisting of naturally occuring alpha-aminocarboxylic acids, neurotransmitters other than such acids, and central or peripheral nervous system pharmacologically active compounds, and containing a functional group including an acylatable hydrogen atom, or a reactive derivative thereof; and (b) an essential fatty acid or a reactive derivative thereof; and including the pharmaceutically acceptable salts of such acylates possessing a basic and (or) acidic function; and to their functional derivatives. The acylates and their functional derivatives may be used for treatment of a disease or condition related to a neurotransmitter defector deficiency, or to another central or peripheral nervous system defect or deficiency, and in particular Parkinson's disease.

Abstract: Diesters of dianhydroglycitols can be prepared by esterification of dianhydroglycitols, anhydroglycitols and/or glycitols with alkylcarboxylic or arylcarboxylic acids in the presence of an acid catalyst, the acid catalyst being a macroporous acid ion exchange resin. If glycitols or monoanhydroglycitols are used as the starting material, the reaction temperature is initially of the order of 120° C. and after the dehydration is approximately 140° C.

Abstract: The invention relates to the use of phenolic compounds and derivatives thereof for protection against neurodegenerative diseases, to compositions comprising these compounds, and to some novel phenolic compounds.

Abstract: Lutein and zeaxanthin, the main carotenoids in marigold flowers, and capsanthin and capsorubin, the main carotenoids in red peppers are esterified mainly with C-18 fatty acids. The pigments were re-esterified without isolating them from the natural saponified extract using carboxylic acids in the range of C-1 to C-12 and their corresponding metallic salts in the presence of a catalyzing agent. Both the diester and monoester forms were obtained. It is expected that the pigment esters with a fatty acid of 12 or less carbons will have a better digestibility than the esters of xanthophylls in their natural state and better stability than the hydrolyzed xanthophylls. This will result in a better pigmentation capacity of the carotenoids for poultry or aquaculture.

Abstract: The present invention refers to the use of phenolic compounds and their derivatives represented by formula I wherein R1 and R2 are selected from among: OH, OCOalkyl, or OCOalkenyl, and R3 is either H, OH, OCOalkyl or OCOalkenyl, wherein the alkyl or alkenyl chains present from 2 to 22 carbon atoms and wherein at least one OCOalkyl or OCOalkenyl group is present in the structure, for the prevention and treatment of cardiovascular, hepatic or renal diseases, as well as to their cosmetic applications, to compositions that include these compounds and to some novel phenolic compounds and derivatives.

Abstract: Process for the esterification of organic acids with alcohols in a reactor of the chromatographic type in which the heterogeneous solid phase is capable of acting both as an esterification catalyst and as a means exhibiting preferential adsorption towards one of the reaction products (typically water). The process to which the present invention relates is particularly improved compared with conventional technology owing to the use, as the means for regenerating the catalyst, of a desorbent to which has been added a second compound, generally the anhydride of the acid used in the esterification reaction, which, by chemical reaction, completes the removal of the adsorbed water.

Abstract: Process for the manufacture of a mixture of fatty acid esters comprising the steps of: (a) hydrolysing a sterol ester or a mixture of sterol esters such that a mixture is obtained comprising phenolic acids and/or fatty acids, and free sterols; and (b) optionally, separating the phenolic acids and/or fatty from the reaction mixture; and (c) esterifying the so obtained free sterols with particular fatty acids.

Abstract: Disclosed is a process for the preparation of aryl carboxylate esters by the reaction of a phenol reactant with an esterification agent selected from carboxylic acid anhydrides and carboxylic acid halides in the presence of trifluoroacetic acid (TFA).

Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

Abstract: The present invention relates to compounds according to the structure: Wherein R1 is a C11 to C21 saturated or unsaturated, linear or branched hydrocarbon or a saturated or unsaturated hydrocarbon containing a pendant hydroxyl group, preferably on a carbon atom in a position alpha or beta to the keto group of the ester moiety; X is CH2, OCH2CH2 or HC═CHCH2; and R2 is H, OCH3, CH3 or CH2CH3. These compounds exhibit use in personal care products as dry emollients as well as providing additional characteristics including solvency, dispersants, gloss-enhancing agents, solubilizing agents and melting-point depressants, lubricants, viscosity modulating agents and skin protection factor boosters.

Abstract: The purpose of the invention is to provide capsaicinoid-like substances to be used as food additives and pharmaceutical ingredients. Capsaicinoid-like substances represented by the following general formula: and food and pharmaceutical compositions comprising them.

Abstract: The invention relates to a process for the preparation of fatty acid partial esters of polyols, the fatty acid partial esters thus obtainable, and their use. The fatty acid partial esters (I) of polyols having at least 4 C atoms, at least one primary and at least one secondary alcohol group of the starting polyols are obtained in a process, where in a first process step the polyols are reacted with a fatty acid or a fatty acid derivative to give a fatty acid partial ester (II) and in a second process step the fatty acid partial esters (II) obtained are subjected to a selective enzymatic cleavage of primary ester groups.

Abstract: The compound 7,10,12-trihydroxy-8(E)-octadecenoic acid (TOD) has been produced by bioconversion of ricinoleic acid by Pseudomonas aeruginosa PR3. TOD and derivatives thereof are useful for controlling biological organisms, such as fungi and insects.

Abstract: The invention relates to compounds of the formula: 1

Abstract: An antiviral agent comprising as an active ingredient a phorbol derivative of formula (I): (wherein R1, R2, R3, R4, and R5, independently one another, represent a hydrogen atom, an aliphatic carboxylic acid residue, or an aromatic carboxylic acid residue) having a ratio r=CC0/IC100, i.e., ratio of concentration CC0 at which survival of MT-4 cells is decreased upon cell proliferation tests to concentration IC100 at which HIV-1-induced cytopathic effect (CPE) on MT-4 cells is inhibited by 100%, of 2 or more and having a protein kinase C(PKC) activation of 30% or less at a concentration of 10 ng/mL. The agent is useful as an anti-HIV agent.

Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

Abstract: Inositol derivatives, compositions comprising inositol derivatives, and methods for using compositions comprising inositol derivatives as agents for inhibiting superoxide anion production are described. The inositol derivatives are obtainable via conventional organic synthesis. The inositol derivatives inhibit superoxide anion produced by neutrophils and macrophages which cause tissue damage.

Abstract: The present invention is directed to free radical polymers, which contain a meadowfoam ester group as one of the functional groups polymerized. The compounds of the invention are prepared by the free radical polymerization of a novel meadowfoam monomer having a reactive vinyl group and a number of other free radical polymerizable reactants. The unique structure of the meadowfoam results in polymers with oxidative stability heretofore unattainable.

Abstract: A compound effect for the treatment of dermatological disorders comprises a mono- or diester of an &agr;,&ohgr;-dicarboxylic acid, wherein the alcohol moiety of the said ester comprises a keratolytically active alcohol. The compound may have the formula, where n is in the range of 6 to 12; m is in the range of 0 to 8; R′ is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR″, CONHR″ and COOR″; R″ is selected from the group consisting of alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

Abstract: The present invention deals with the composition of matter and the utilization of certain novel sorbitol guerbet esters which are prepared by the reaction of a guerbet acid and a sorbitol as emulsifiers.

Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

Abstract: A novel compound, 12,13,17-trihydroxy-9(Z)-octadecenoic acid (THOA) was produced from linoleic acid by microbial transformation at 25% yield. The newly isolated microbial strain catalyzing this transformation was identified as Clavibacter sp. ALA2 (Accession No. NRRL B-21660). THOA and its derivatives have application as antifungal agents.

Abstract: A biodegradable lubricant which is prepared from: about 60-99% by weight of at least one biodegradable synthetic ester base stock which comprises the reaction product of: a branched or linear alcohol having the general formula R(OH).sub.n, wherein R is an aliphatic or cyclo-aliphatic group having from about 2 to 20 carbon atoms and n is at least 2; and mixed acids comprising about 30 to 80 molar % of a linear acid having a carbon number in the range between about C.sub.5 to C.sub.12, and about 20 to 70 molar % of at least one branched acid having a carbon number number in the range between about C.sub.5 to C.sub.13 ; wherein the ester base stock exhibits the following properties: at least 60% biodegradation in 28 days as measured by the Modified Sturm test; a pour point of less than -25.degree. C; and a viscosity of less than 7500 cps at -25.degree. C; about 1 to 20% by weight lubricant additive package; and about 0 to 20% of a solvent.

Abstract: The present invention relates to the use of some natural or synthetic chalcones and the esters thereof with straight or branched aliphatic acids, saturated and unsaturated, containing up to 22 carbon atoms in the therapy and prevention of the uterus, ovary and breast tumors, as well as the formulations containing them. Chalcones such as isocordoin, cordoin, 2-hydroxyderricin, 2',4'-dihydroxychalcone, 4,2',4'-trihydroxychalcone have a marked affinity to the estrogen receptors of type II and an antiproliferative activity on uterus, ovary and breast tumor cell lines. These molecules proved to be useful both in therapy and in the prevention of such tumors.

Abstract: The present invention also relates to a method of treating aspirin-treatable conditions comprising administering to a patient in need of such treatment a compound of Formula I ##STR1##

Abstract: Water or lipid soluble, pharmacologically active, antioxidant, anti-phospholipase compounds that are chemically defined. The compounds protect mammalian cells by inhibiting PLA.sub.2 and preventing oxidation. In particular, each compound has at least two fatty moieties and no active hydroxy group. The compound may also have at least one ionizable group, which may a carboxyl group, and each of the fatty moieties has from sixteen to twenty carbon atoms and at least one cis-unsaturated double bond.

Abstract: Compounds of formula (I): ##STR1## in which: R represents hydrogen, methyl or hydroxy; X represents an alkyl, alkenyl, cycloalkyl, aryl, aralkyl, or heterocyclic group; A represents a single bond, or an alkylene, alkenylene, alkynylene or alkadienylene group; Y represents hydrogen, or an aryl, cycloalkyl or heterocyclic group; have valuable antihypercholesteremic activities and may be used in the treatment of disorders arising from a blood cholesterol imbalance in humans and other animals.

Abstract: The present invention provides a salicylate analogue having the structure ##STR1## wherein R is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl; pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, phenyl, naphthyl and cyclohexyl; wherein R1 is selected from the group consisting of hydrogen, a C1-C12 alkyl group, F, Cl, Br, I, CO.sub.2 H, CONHR, CONR.sub.2, CO.sub.2 R, C.tbd.N, CHO, COR, SO.sub.3, SO.sub.2 NHR, SO.sub.2 NR.sub.2, OH, OR, OCOR, SH, SR, OCONHR, OCONR.sub.2, SCOR, SCONHR, SCONR.sub.2 and NH2, NHR, NHCOR and NR2; and wherein R1 is in the 3-, 4-, 5- or 6-position, or a combination thereof. Also provided are various pharmaceutical compositions of the novel compounds of the present invention.